Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511
about
Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on AsparaginaseAsparaginase pharmacokinetics and implications of therapeutic drug monitoringHow to manage asparaginase hypersensitivity in acute lymphoblastic leukemiaPegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trialArginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy.Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studiesOutcomes of a modified CALGB 19802 regimen in adult acute lymphoblastic leukemia.Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia.Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study.First-line treatment of acute lymphoblastic leukemia with pegasparaginase.Adult acute lymphoblastic leukemia: concepts and strategies.PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma.Peg-asparaginase for acute lymphoblastic leukemia.Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.L-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia.Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.Enzymes approved for human therapy: indications, mechanisms and adverse effects.A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.Albumin/asparaginase capsules prepared by ultrasound to retain ammonia.Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU.The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.Redefining transplant in acute leukemia.A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia.Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.Pre-Transplant Consolidation is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL): the use of dexamethasone, L-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL.Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.Monitoring of asparagine depletion and anti-L-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial.PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity
P2860
Q26784116-5B0076AB-3F16-4CE5-AF01-B277B3245683Q27026476-98E97AAD-3696-49D3-8FD3-C05D1E5EF97AQ27026952-AF17907A-3B2D-4409-A478-295C1C9FE83AQ31118945-F84F55F8-71E6-411F-8860-3F413ED07263Q34314481-E78CCDE9-595E-4618-80DF-E4419CCD522BQ35659879-421E9367-3CF8-41E1-8191-FDD9EF987858Q36843677-2BCB8149-0CD6-4B41-8102-0D4FE6C0F4B7Q36854190-289FBE36-30AC-45F6-845E-75C3B70D4F55Q37080458-8E0E7B72-367E-489C-8C37-952B1172A7F4Q37522294-F436E525-D929-4E52-B157-365D1686A66AQ37586935-C896845D-70C4-408B-A84B-39AD56C65DC4Q37681450-93C2DA80-EB9C-416C-95A2-B1B3C39695D4Q37697320-D972C1E8-9848-4940-B1CE-5A92913D315BQ37719558-EF0C34F7-AF61-4E17-9CB2-2E05FF326EB9Q37914185-0A192453-A45A-4E75-833E-7CCD15F0319EQ38017602-E5CB43A5-DF0B-410C-BEB9-0F811190E8B8Q38079075-800CE25F-E3E0-4F4E-889D-DA85DCA233DCQ38342838-1857464B-D3BB-48B7-8BD5-523B85B8699EQ38409519-2BF0D1C6-CFCE-476A-9174-DEEEFD2CE351Q38740125-69389B60-9E3B-462C-B8B4-BFFE76F1DD59Q39258365-468F869A-BCB4-43DA-8740-1BD30F953F8BQ39387524-A6A182C6-FF07-4064-B455-69FF6C0BC067Q39396416-8DBF9783-98D9-434A-92CF-454CBB460649Q40243523-6688BCED-D138-4402-A1A2-F5D865CAD8FFQ44657508-B35D1FC7-2CF8-4D83-8E7F-B51BEAEFAC9EQ45785797-7B7AB7AE-AC0D-40D0-801F-558BAF34984DQ47434135-5EB69EFC-2FDA-4248-9AD3-F27F7DA66413Q47564576-3D847717-43DF-4864-B2E0-1C7098ED5AF8Q48166631-52580F40-B2F5-437B-80D3-BF168DF7527BQ49730092-086F4E37-C4B3-47BE-83A1-F63305DF57CAQ49818206-2083F35F-9F2F-4C1E-8B81-9B30C384A7DBQ52915505-86F1F013-49CC-445E-8EDB-45BD23DED7F8Q53713010-1F69BDB3-8962-4657-9E78-68F49DBBAC78Q55340882-91F52293-63EC-44D0-9B4D-2167BE68C623Q58706446-60B339D0-EAD8-4EDE-9247-FE0E6D41F435
P2860
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Effective asparagine depletion ...... nd Leukemia Group B Study 9511
@ast
Effective asparagine depletion ...... nd Leukemia Group B Study 9511
@en
type
label
Effective asparagine depletion ...... nd Leukemia Group B Study 9511
@ast
Effective asparagine depletion ...... nd Leukemia Group B Study 9511
@en
prefLabel
Effective asparagine depletion ...... nd Leukemia Group B Study 9511
@ast
Effective asparagine depletion ...... nd Leukemia Group B Study 9511
@en
P2093
P2860
P1433
P1476
Effective asparagine depletion ...... nd Leukemia Group B Study 9511
@en
P2093
Bayard L Powell
Ben L Sanford
Divino DeOliveira
Joanne Kurtzberg
Jonathan E Kolitz
Meir Wetzler
Richard A Larson
Stanley R Frankel
P2860
P304
P356
10.1182/BLOOD-2006-09-045351
P407
P577
2007-01-30T00:00:00Z